cyclic radiopeptide PSV-359 targeting FAP-alpha (Perspective Therapeutics)

N/A

Report date: 2025/06/11 10:43:21

Base Information

Drug Namecyclic radiopeptide PSV-359 targeting FAP-alpha (Perspective Therapeutics)
Drug Alias Name[212Pb]-PSV-359 + [203Pb]-PSV-359212Pb-PSV-359 + 203Pb-PSV-359Lead-203-PSV-359 + Lead-212-PSV-359[203Pb]-PSV-359 + [212Pb]-PSV-359203Pb-PSV-359 + 212Pb-PSV-359 +[7] 
ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Recombinant polypeptideRadiation-emitting products > Radioactive diagnostic agent +[4] 
Mechanisms of ActionFibroblast activation protein alpha inhibitorsSPECT contrast agent
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPerspective Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPerspective Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A